Skip to content

Treatment of hypotension of prematurity: a non-blinded cohort clinical trial

Treatment of hypotension of prematurity: a non-blinded cohort clinical trial - TOHOP trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON34563
Enrollment
150
Registered
2011-04-19
Start date
2011-09-19
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension low blood pressure

Interventions

Patients randomized to *Group A* will be treated for hypotension according to the treatment protocol operative in the NICU at the UMCU. Patients randomized to *Group B* will receive no cardiovascula
and/or urine output

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Preterm infants with gestational age

Exclusion criteria

Exclusion criteria: Prior to inclusion indirect clinical (capillary refill;urine production) or direct laboratory evidence (lactate) of poor organ/tissue perfusion, intra uterine exposure to excessive maternal vasoactive medication , severe clinically or microbiologically proven sepsis or congenital malformations

Design outcomes

Primary

MeasureTime frame
To determine whether refraining (group B) from anti-hypotensive treatment has a negative, positive or no effect on the composite outcome of mortality and neurodevelopmental outcome (determined by BSID-III) at 24 months of age.

Secondary

MeasureTime frame
Secondary outcome measures will include 1) differences between the groups in the incidence of PIVH during the first 7 postnatal days detected by head ultrasound, 2) differences in the incidence of white matter injury PVL and gray matter injury not detected within the first 7 days by ultrasound using advanced MRI parameters of the brain at the adjusted postmenstrual age of 40 weeks as well as the ability to maintain CBF autoregulation during the first three postnatal days.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)